Development of an Innovative Bispecific Engager Simultaneously Binding Pd-L1 and Cd28 to Reverse Immunosuppressive Tumor Microenvironment for Enhancing Anti-Cancer Efficacy of T Cell-Based Therapies

Keywords

• anti-PD-L1/anti-CD28 bi-functional protein drug
• PD-1/anti-CD28 bi-functional protein drug
• T cell therapy
• solid tumor treatment
• reverse tumor microenvironment
• blocking PD-L1/PD-1inhibiotry signal
• activating CD28 signal